Inicio>>Signaling Pathways>> Microbiology & Virology>> Virus Protease>>NGI-1 (ML414)

NGI-1 (ML414) (Synonyms: N-linked Glycosylation Inhibitor 1)

Catalog No.GC33055

NGI-1 (ML414) (ML414) es un potente inhibidor de la oligosacariltransferasa (OST), que se dirige directamente y bloquea la funciÓn de las subunidades catalÍticas de la OST STT3A y STT3B. NGI-1 (ML414) es un inhibidor permeable a las células y puede reducir eficazmente la infectividad del virus sin afectar la viabilidad celular.

Products are for research use only. Not for human use. We do not sell to patients.

NGI-1 (ML414) Chemical Structure

Cas No.: 790702-57-7

Tamaño Precio Disponibilidad Cantidad
10mM (in 1mL DMSO)
50,00 $
Disponible
5mg
45,00 $
Disponible
10mg
72,00 $
Disponible
50mg
252,00 $
Disponible
100mg
403,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

NGI-1 is a cell permeable inhibitor.

NGI-1 blocks EGFR N-linked glycosylation in lung adenocarcinoma cells as assessed. In controls EGFR is biotinylated, consistent with its plasma membrane expression, but in NGI-1 treated cells the EGFR is predominantly found in the non-biotinylated intracellular fraction suggesting a change in cellular localization[1].

[1]. Lopez-Sambrooks C, et al. Oligosaccharyltransferase inhibition induces senescence in RTK-driven tumor cells. Nat Chem Biol. 2016 Dec;12(12):1023-1030.

Reseñas

Review for NGI-1 (ML414)

Average Rating: 5 ★★★★★ (Based on Reviews and 7 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for NGI-1 (ML414)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.